-- 週三,德國藍籌股DAX指數變動不大,收盤上漲0.18%。投資人權衡中東持續衝突、繁忙的企業財報季以及歐元區最新工業產出數據之間的關係。 根據歐盟統計局的數據,歐元區2月工業生產季增0.4%,低於先前修正後的0.8%的降幅和預期的0.3%的成長。這項樂觀數據反映了中間產品、資本貨物和非耐用消費品產量的成長。以年計算,歐元區工業生產下降0.6%,與先前修正後的0.6%的降幅一致,也低於預期的1%的降幅。 「儘管貿易動盪嚴重,歐元區工業在2025年依然展現出極強的韌性。但2026年初的情況並不樂觀。隨著美國企業提前採購的步伐放緩,生產水準再次下降。雖然製造商對基礎設施和國防投資承諾的樂觀情緒有所回升,但中東戰爭卻粉碎了全面復甦的希望。 聚焦德國,德國企業的不確定性達到了2024年2月以來的最高水準。 ifo經濟研究所的報告顯示,78.6%的受訪企業表示,在持續不斷的伊朗戰爭中,預測未來發展「困難或相當困難」。 ifo指出,製造業的不確定性“尤為顯著”,87.7%的企業受到影響,持續的結構性不利因素繼續對該行業構成壓力。 企業新聞方面,德意志銀行研究部預計寶馬集團(BMW.F)將在5月6日發布的第一季財報中維持其業績展望,因為市場已經消化了2026年「疲軟開局」的預期。 「集團第一季銷量年減3.5%,主要原因是中國市場兩位數下滑和美國市場個位數中段下滑,而歐洲市場則增長了3%。車型方面,X3表現強勁,而幾乎所有其他車型的銷量均有所下降。我們了解到,新款iX3也提振了訂單量,歐洲市場的訂單量實現了兩位數增長,並且這一盈利能力將持續到下半年。 、原材料成本、關稅、研發資本投入減少以及折舊等因素將對盈利能力構成不利影響,但效率提升將部分抵消這些不利因素。 儘管如此,在寶馬一貫的成本季節性因素的支撐下,汽車業務的息稅前利潤率預計將在4%至6%的範圍內預測資金。 BMW股價收盤下跌0.32%。 同時,Evotec (EVT.F) 任命 Ingrid Müller 為營運長,自 5 月 1 日起生效。 Müller 先前任職於 CureVac,這是一家德國 mRNA 疫苗開發商,於 2025 年被其同行 BioNTech 收購。 Evotec 在 Xetra 交易所的股價上漲了 2.88%。
Related Articles
Research Alert: CFRA Maintains Hold Rating On Shares Of United Rentals Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target price to $1,100 from $950 following a strong first quarter, valuing shares at 20.5x our 2027 EPS outlook of $54.28 (in line with previous estimate; 2026 EPS also in line). We believe a higher multiple is justified given URI's firming market leadership within an expanding rental equipment industry. A robust Q1 beat enabled URI to raise its full-year revenue guidance to $16.9B-$17.4B and adjusted EBITDA to $7.625B-$7.875B, citing momentum heading into a busy season. With leverage well below historical levels, we believe accretive M&A deals could serve as a potential catalyst for additional guidance increases. Margin compression has been a sticky issue for URI, but Q1 indicated that pricing may have turned around and that headwinds are starting to ease as quarterly results begin to lap when tariff-related inflation began to pick-up. We remain cautious on margins, though are encouraged by signs of stabilization. New project activity is likely supporting pricing trends, in our view.
Petro Rabigh Emerges From Loss in Q1; Revenue Grows
Rabigh Refining and Petrochemical (SASE:2380), d/b/a Petro Rabigh, said Sunday it swung back to profit in the first quarter of 2026, while revenue increased year over year.Net profit attributable to shareholders of the issuer for the three months ended March 31 was 1.47 billion Saudi riyals, compared with the attributable loss of 691 million riyals earlier. EPS moved to 0.88 riyal from a loss per share of 0.41 riyal.The Tadawul-listed oil refining and petrochemical company's revenue was 14.85 billion riyals, compared with 11.21 billion riyals a year ago.
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.